| Title |
Superior efficacy of Adalimumab in treating childhood refractory chronic uveitis when used as first biologic modifier drug: Adalimumab as starting anti-TNF-α therapy in childhood chronic uveitis
|
|---|---|
| Published in |
Pediatric Rheumatology, April 2013
|
| DOI | 10.1186/1546-0096-11-16 |
| Pubmed ID | |
| Authors |
Gabriele Simonini, Andrea Taddio, Marco Cattalini, Roberto Caputo, Cinzia de Libero, Fulvio Parentin, Ilaria Pagnini, Loredana Lepore, Rolando Cimaz |
| Abstract |
Nonetheless biologic modifier therapies are available treatment strategies for sight-threatening uveitis in children, the lack of evidence from head-to-head randomized controlled studies limits our understanding of timing of therapy when to commence therapy, which agent to choose and how long to continue treatment, and, in case of failure, if switching to another anti-TNF-α strategy might be eventually an option. Our aim was to compare the efficacy of Adalimumab when used as first anti-TNFα therapy versus Adalimumab used after the failure of a previous anti-TNFα (Infliximab) in an open-label, comparative, multi-center, cohort study of childhood chronic uveitis. |
Mendeley readers
The data shown below were compiled from readership statistics for 75 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Denmark | 1 | 1% |
| Canada | 1 | 1% |
| Unknown | 73 | 97% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Ph. D. Student | 13 | 17% |
| Researcher | 11 | 15% |
| Other | 10 | 13% |
| Student > Postgraduate | 10 | 13% |
| Student > Master | 8 | 11% |
| Other | 13 | 17% |
| Unknown | 10 | 13% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 47 | 63% |
| Pharmacology, Toxicology and Pharmaceutical Science | 5 | 7% |
| Agricultural and Biological Sciences | 2 | 3% |
| Computer Science | 2 | 3% |
| Neuroscience | 2 | 3% |
| Other | 4 | 5% |
| Unknown | 13 | 17% |
Attention Score in Context
This research output has an Altmetric Attention Score of 8. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 04 April 2018.
All research outputs
#4,087,320
of 22,711,242 outputs
Outputs from Pediatric Rheumatology
#140
of 692 outputs
Outputs of similar age
#35,067
of 197,213 outputs
Outputs of similar age from Pediatric Rheumatology
#2
of 10 outputs
Altmetric has tracked 22,711,242 research outputs across all sources so far. Compared to these this one has done well and is in the 81st percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 692 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 5.6. This one has done well, scoring higher than 79% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 197,213 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 82% of its contemporaries.
We're also able to compare this research output to 10 others from the same source and published within six weeks on either side of this one. This one has scored higher than 8 of them.